Lyra Health Raises $200M for Mental Health
Lyra Health, a Burlingame CA-based company which specializes in comprehensive mental health care benefits, raised $200M in funding. The round was led by Coatue joined by new investor Sands Capital, along with existing investors.
“One in five people struggle with mental health challenges such as anxiety, depression, or substance use disorder,” said David Ebersman, Lyra Health CEO and co-founder. “Delivering mental health care for diverse employee populations around the world is one of the most pressing and complex issues for employers today, and this new funding will help Lyra accelerate our plans to deliver comprehensive, global solutions.”
Lyra delivers mental health for employees and family members at leading multinational companies, including eBay; Genentech, a member of the Roche Group; Uber; and VCA Animal Hospitals. Lyra currently serves more than 2.2 million members globally.
With the new funding, the company plans to accelerate the delivery of its benefits for companies with employees located around the world and enhance its international solutions.
Announcement: Lyra Health Raises $200M for Mental Health


Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients
1 Department of Cancer Medicine, Adult Sarcoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy
2 Department of Pathology, Experimental Molecular Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy
3 Department of Anatomic Pathology, General Hospital of Treviso, P.zza Ospedale 1, Treviso, 31100, Italy
4 Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy
Clinical Sarcoma Research 2013, 3:4 doi:10.1186/2045-3329-3-4Published: 3 April 2013
We explore the pattern of late recurrence (LR) in solitary fibrous tumor (SFT), focusing on histopathologic characteristics, clinical presentation and patients (pts) outcome.
Clinical records of all pts with confirmed pathologic diagnosis of SFT treated at our Institution from 2005 to 2011 were reviewed. We analysed the data of pts who relapsed ≥10 years after initial diagnosis.
A total of 14 pts were identified. The primary site of origin was pleura (5 pts), pelvis (4 pts), head and neck (3 pts) and retroperitoneum (2 pts). Primary tumor was a typical SFT in 5 and a malignant SFT in 7 out of 12 pts whose tumor tissue was available for revision. The median time to first recurrence was 12 years (range 10–23). The first relapse was local in 11 cases, distant in 3. Five pts later developed distant metastases. Four out of 5 cases of typical SFT developed distant metastases in spite of their initial benign aspect. No patient was disease-free at the time of the analyses.
Our series suggests that LR can occur in SFT and some cases can behave aggressively even in the absence of any primary morphologic evidence of malignancy. A prolonged follow-up may be advisable.